Visus Therapeutics
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Nickerson St Ste 101, Seattle, Washing...Phone Number
(800) 281-4536Website
www.visustx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Visus Therapeutics
Visus Therapeutics, headquartered in Seattle, Washington, is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world.Explore more
Visus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Visus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Visus Therapeutics is spiking on competitors!
Visus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Visus Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Visus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Visus Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Visus Therapeutics
Click to see if Visus Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Visus Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Visus Therapeutics
Find 2 more new buyers
Compare Similar Companies to Visus Therapeutics
Compare insights from companies similar to Visus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Visus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Visus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Visus Therapeutics.
Visus Therapeutics financials insights
Gather financial insights about Visus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$36M
Stock Offering
$20M
Visus Therapeutics Tech Stack
A closer look at the technologies used by Visus Therapeutics
Most Recent Scoops
Event
Product Marketing, Events, Training, Learning & Development, Medical Education & Training, Field /Outside Sales, Field Marketing, Optometry
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Event
Events
Event
Events
New Hire
Executive Move
Executive Moves, New Hire
Visus Therapeutics News & Media
Presbyopia Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies - Eyenovia, Orasis, Ocuphire Pharma, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, AbbVie
The presbyopia market is predicted to grow during the forecast period (2023–2032) owing to the development of well-designed, randomized trials to study novel drugs with potential benefits for Presbyopia patients, the shortfall of approved therapy, and the launch of emerging therapies. The presbyopia market is predicted to grow during the forecast period (2023–2032) owing to the development of well-designed, randomized trials to study novel drugs with potential benefits for Presbyopia patients, tVisus Therapeutics to Present at the Baird 2023 Global Healthcare Conference
SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2023 Global Healthcare Conference on September 12th, 2023, at the InterContinental New York Barclay hotel. The presentation is scheduled for 8:30 AM Eastern Time on Tuesday, SeptembeVisus Therapeutics to Present at 2023 JMP Securities Life Science Conference
SEATTLE & IRVINE, Calif--(BUSINESS WIRE)-- #VisusTx--Visus Therapeutics to present at the 2023 JMP Securities Life Science Conference on May 15. A live webcast of the presentation will be available.Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023
SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial. The study evaluating the safety and efficacy of BRIMOCHOL™ PF, a preservative-free ophthalmic solution for the treatment of presbyopia, met its primary and secondary endpoints. BRIMOCHOL™ PF successf
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Visus Therapeutics
Sign Up For FreeTo access detailed company insights
Visus Therapeutics, headquartered in Seattle, Washington, is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world.... Read More
